Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
NOVATO, Calif., Aug. 21, 2025 ( GLOBE NEWSWIRE ) -- Ultragenyx Pharmaceutical Inc. ( NASDAQ: RARE ) , a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of 113,572 restricted stock units of ...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO - Mereo BioPharma Group ( NASDAQ:MREO )
NEW YORK, Aug. 21, 2025 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of Mereo BioPharma Group plc ( "Mereo" or the "Company" ) MREO. Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE - Ultragenyx Pharmaceutical ( NASDAQ:RARE )
NEW YORK, Aug. 21, 2025 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of Ultragenyx Pharmaceutical Inc. ( "Ultragenyx" or the "Company" ) RARE. Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE - Ultragenyx Pharmaceutical ( NASDAQ:RARE )
NEW YORK, Aug. 17, 2025 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of Ultragenyx Pharmaceutical Inc. ( "Ultragenyx" or the "Company" ) RARE. Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO - Mereo BioPharma Group ( NASDAQ:MREO )
NEW YORK, Aug. 13, 2025 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of Mereo BioPharma Group plc ( "Mereo" or the "Company" ) MREO. Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Mereo BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Highlights
Data from Phase 3 Orbit and Cosmic studies of setrusumab in osteogenesis imperfecta expected around ...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO - Mereo BioPharma Group ( NASDAQ:MREO )
NEW YORK, Aug. 09, 2025 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of Mereo BioPharma Group plc ( "Mereo" or the "Company" ) MREO. Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Ultragenyx's Q2 Loss Narrower Than Expected, Revenues Rise Y/Y
RARE posts a narrower Q2 loss and 13% revenue growth as demand rises across all four marketed rare disease drugs.
Ultragenyx ( RARE ) Q2 Revenue Up 13%
Ultragenyx Pharmaceutical ( NASDAQ:RARE ) , a rare disease drug developer, reported its second quarter 2025 earnings on August 5, 2025. Both revenue and earnings per share exceeded Wall Street expectations for the period.
Ultragenyx to Host Conference Call for Second Quarter 2025 Financial Results and Corporate Update
NOVATO, Calif., July 30, 2025 ( GLOBE NEWSWIRE ) -- Ultragenyx Pharmaceutical Inc. ( NASDAQ: RARE ) , a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced that it will host a conference ...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO - Mereo BioPharma Group ( NASDAQ:MREO )
NEW YORK, July 28, 2025 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of Mereo BioPharma Group plc ( "Mereo" or the "Company" ) MREO. Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
NOVATO, Calif., July 18, 2025 ( GLOBE NEWSWIRE ) -- Ultragenyx Pharmaceutical Inc. ( NASDAQ: RARE ) , a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of 45,292 restricted stock units of the ...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE - Ultragenyx Pharmaceutical ( NASDAQ:RARE )
NEW YORK, July 18, 2025 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of Ultragenyx Pharmaceutical Inc. ( "Ultragenyx" or the "Company" ) RARE. Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
FDA Delays Approval For Ultragenyx's Gene Therapy, But Not A Dealbreaker, Says Analyst - Ultragenyx Pharmaceutical ( NASDAQ:RARE )
FDA issued a Complete Response Letter for Ultragenyx's UX111 gene therapy, citing manufacturing facility issues. Morgan Stanley cuts Ultragenyx's price target to $55 from $65; Wedbush lowers it to $34. PPI and Industrial Production drop Wednesday morning - see how Matt Maley is trading the ...
Ultragenyx Pharmaceutical, Apple And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Apple ( NASDAQ:AAPL ) , Above Food Ingredients ( NASDAQ:ABVE )
U.S. stock futures were lower this morning, with the Dow futures falling around 100 points on Monday. Shares of Ultragenyx Pharmaceutical Inc. RARE fell sharply in pre-market trading. Ultragenyx received a Complete Response Letter from the FDA for UX111 AAV gene therapy to treat Sanfilippo ...
Ultragenyx Receives Complete Response Letter from FDA for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A ( MPS IIIA )
Complete Response Letter ( CRL ) cited specific chemistry, manufacturing and controls ( CMC ) related observations that are resolvable ...
Ultragenyx Pharmaceutical's Options: A Look at What the Big Money is Thinking - Ultragenyx Pharmaceutical ( NASDAQ:RARE )
Financial giants have made a conspicuous bearish move on Ultragenyx Pharmaceutical. Our analysis of options history for Ultragenyx Pharmaceutical RARE revealed 10 unusual trades. Delving into the details, we found 30% of traders were bullish, while 60% showed bearish tendencies.
Crude Oil Down Over 2%; Delta Air Lines Posts Upbeat Earnings - BIT Mining ( NYSE:BTCM ) , Above Food Ingredients ( NASDAQ:ABVE )
U.S. stocks traded mostly higher midway through trading, with the Dow Jones index gaining more than 200 points on Thursday. The Dow traded up 0.52% to 44,690.50 while the NASDAQ declined 0.03% to 20,605.11. The S&P 500 also rose, gaining, 0.23% to 6,278.25. Health care shares jumped by 1.2% on ...
US Stocks Mixed; Initial Jobless Claims Fall - BIT Mining ( NYSE:BTCM ) , Above Food Ingredients ( NASDAQ:ABVE )
U.S. stocks traded mixed this morning, with the Dow Jones index gaining around 100 points on Thursday. Following the market opening Thursday, the Dow traded up 0.24% to 44,564.14 while the NASDAQ declined 0.44% to 20,520.54. The S&P 500 also fell, dropping, 0.09% to 6,257.81.
RARE, MREO Fall as Osteogenesis Study Likely to Continue Till Year End
Ultragenyx Pharmaceutical and Mereo BioPharma shares tumble as investors await key phase III UX143 osteogenesis data now set for release at year-end.
Why Are Biotech Stocks Ultragenyx And Mereo Facing A Sell-Off? - Ultragenyx Pharmaceutical ( NASDAQ:RARE ) , Mereo BioPharma Group ( NASDAQ:MREO )
UX143 Phase 3 trial will continue to final analysis as interim data did not meet early stopping criteria ( p<0.01 ) . Final analysis for Orbit and Cosmic trials expected by year-end, with thresholds of p<0.04 and p<0.05 respectively. Up Next: Get 5 Dark Horse Stocks Wall Street Is Quietly ...
Methode Electronics, Ultragenyx Pharmaceutical And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - BitMine Immersion Techs ( AMEX:BMNR ) , Altimmune ( NASDAQ:ALT )
U.S. stock futures were lower this morning, with the Dow futures falling around 100 points on Thursday. Shares of Methode Electronics, Inc. MEI fell sharply in today's pre-market trading after the company reported a fourth-quarter adjusted EPS miss.
RARE's GTX-102 Gets FDA's Breakthrough Status for Angelman Syndrome
Ultragenyx Pharmaceuticals' GTX-102 earns FDA Breakthrough status after early data shows sustained progress in Angelman syndrome patients.
Ultragenyx Receives Breakthrough Therapy Designation for GTX-102 in Angelman Syndrome - Ultragenyx Pharmaceutical ( NASDAQ:RARE )
Phase 3 Aspire study enrollment on track to complete in 2025 Aurora study to evaluate GTX-102 in other Angelman syndrome genotypes and ages expected to initiate later this year NOVATO, Calif., June 27, 2025 ( GLOBE NEWSWIRE ) -- Ultragenyx Pharmaceutical Inc.
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635 ( c ) ( 4 ) - Ultragenyx Pharmaceutical ( NASDAQ:RARE )
NOVATO, Calif., June 20, 2025 ( GLOBE NEWSWIRE ) -- Ultragenyx Pharmaceutical Inc. RARE, a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of 48,731 restricted stock units of the company's ...
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
NOVATO, Calif., June 20, 2025 ( GLOBE NEWSWIRE ) -- Ultragenyx Pharmaceutical Inc. ( NASDAQ: RARE ) , a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of 48,731 restricted stock units of the ...
Ultragenyx to Participate at Goldman Sachs 46th Annual Global Healthcare Conference
NOVATO, Calif., June 03, 2025 ( GLOBE NEWSWIRE ) -- Ultragenyx Pharmaceutical Inc. ( NASDAQ: RARE ) , a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Emil Kakkis, M.D., Ph.D., ...
Analyst Bullish On Ultragenyx, Poised For Growth With Six Drug Approvals Expected By 2028 - Ultragenyx Pharmaceutical ( NASDAQ:RARE )
Ultragenyx's Q1 2025 revenue rose 28% to $139.29 million; full-year guidance was set at $640 million-$670 million. Setrusumab is projected to generate $2.4 billion in peak sales by 2037, with $1.4 billion to Ultragenyx.
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
NOVATO, Calif., May 20, 2025 ( GLOBE NEWSWIRE ) -- Ultragenyx Pharmaceutical Inc. ( NASDAQ: RARE ) , a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of 44,805 restricted stock units of the ...
Ultragenyx Underscores Continued Commitment to Rare Disease Innovation with 2024 Impact Report - Ultragenyx Pharmaceutical ( NASDAQ:RARE )
NOVATO, Calif., May 14, 2025 ( GLOBE NEWSWIRE ) -- Ultragenyx Pharmaceutical Inc. RARE released its 2024 Impact Report today, which covers the company's approach to corporate responsibility.
Ultragenyx Underscores Continued Commitment to Rare Disease Innovation with 2024 Impact Report
NOVATO, Calif., May 14, 2025 ( GLOBE NEWSWIRE ) -- Ultragenyx Pharmaceutical Inc. ( NASDAQ: RARE ) released its 2024 Impact Report today, which covers the company's approach to corporate responsibility. The report highlights efforts to transform the lives of individuals and families affected by ...
Mereo BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate Highlights
Progress continues in Phase 3 Orbit study of setrusumab in osteogenesis ...
Ultragenyx's Q1 Loss Wider Than Expected, Revenues Increase Y/Y
RARE reports weaker-than-expected first-quarter results, as earnings and revenues miss estimates despite a year-over-year increase in product sales.
5 Drug/Biotech Stocks Likely to Outperform Q1 Earnings Estimates
Let us look at some drug/biotech stocks, NVO, PCRX, RARE, ACAD and DNLI, which are poised to beat on first-quarter 2025 earnings.
Ultragenyx to Host Conference Call for First Quarter 2025 Financial Results and Corporate Update - Ultragenyx Pharmaceutical ( NASDAQ:RARE )
NOVATO, Calif., April 30, 2025 ( GLOBE NEWSWIRE ) -- Ultragenyx Pharmaceutical Inc. RARE, a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced that it will host a conference call at 5:00 ...
Ultragenyx to Host Conference Call for First Quarter 2025 Financial Results and Corporate Update
NOVATO, Calif., April 30, 2025 ( GLOBE NEWSWIRE ) -- Ultragenyx Pharmaceutical Inc. ( NASDAQ: RARE ) , a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced that it will host a conference ...
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
NOVATO, Calif., April 22, 2025 ( GLOBE NEWSWIRE ) -- Ultragenyx Pharmaceutical Inc. ( NASDAQ: RARE ) , a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare diseases, today reported the grant of 36,831 restricted stock units of the ...
Ultragenyx Stays On JPMorgan's Focus List As Analyst Highlights Strong Long-Term Positioning - Ultragenyx Pharmaceutical ( NASDAQ:RARE )
Ultragenyx's Phase 3 Orbit trial for setrusumab in osteogenesis imperfecta moves toward a second interim analysis in mid-2025. JP Morgan raises Ultragenyx's price target to $117, citing updated setrusumab revenue projections and pipeline additions.
Mereo BioPharma Reports Full Year 2024 Financial Results and Provides Corporate Highlights
Orbit Phase 3 study of setrusumab in osteogenesis imperfecta progressing toward second interim analysis, expected ...
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
NOVATO, Calif., March 19, 2025 ( GLOBE NEWSWIRE ) -- Ultragenyx Pharmaceutical Inc. ( NASDAQ: RARE ) , a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare diseases, today reported the grant of 21,806 restricted stock units of the ...
Alkaptonuria Therapeutics Market to Reach US$ 31.6 Million by 2035 with Rising Demand for Orphan Drugs - Exclusive Report by Transparency Market Research, Inc.
Wilmington, Delaware, Transparency Market Research, Inc. -, March 18, 2025 ( GLOBE NEWSWIRE ) -- Advancements in rare disease treatments and increasing awareness are driving market growth. The Global Alkaptonuria Therapeutics Market Size was valued at US$ 14.7 Million in 2024 and is projected to ...
Mereo BioPharma to Participate in Fireside Chat at the Leerink Partners Global Healthcare Conference
LONDON, March 05, 2025 ( GLOBE NEWSWIRE ) -- Mereo BioPharma Group plc ( NASDAQ: MREO ) ( "Mereo" or the "Company" ) , a clinical-stage biopharmaceutical company focused on rare diseases, today announced that Dr. Denise Scots-Knight, Chief Executive Officer, will participate in a fireside chat ...
Ultragenyx to Participate at Investor Conferences in March
NOVATO, Calif., Feb. 24, 2025 ( GLOBE NEWSWIRE ) -- Ultragenyx Pharmaceutical Inc. ( NASDAQ: RARE ) , a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, today announced participation in three upcoming ...
Ultragenyx to Participate at Investor Conferences in March - Ultragenyx Pharmaceutical ( NASDAQ:RARE )
NOVATO, Calif., Feb. 24, 2025 ( GLOBE NEWSWIRE ) -- Ultragenyx Pharmaceutical Inc. RARE, a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, today announced participation in three upcoming investor ...
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
NOVATO, Calif., Feb. 19, 2025 ( GLOBE NEWSWIRE ) -- Ultragenyx Pharmaceutical Inc. ( NASDAQ: RARE ) , a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare diseases, today reported the grant of 23,760 restricted stock units of the ...
Ultragenyx Q4 Loss Wider Than Expected, Revenues Increase Y/Y
RARE reports mixed fourth-quarter results, as earnings miss estimates while revenues beat the same. Product sales increase year over year.
Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2024 Financial Results and Corporate Update - Ultragenyx Pharmaceutical ( NASDAQ:RARE )
NOVATO, Calif., Feb. 06, 2025 ( GLOBE NEWSWIRE ) -- Ultragenyx Pharmaceutical Inc. RARE, a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultrarare genetic diseases, today announced that it will host a conference call at 5:00 p.m.
Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2024 Financial Results and Corporate Update
NOVATO, Calif., Feb. 06, 2025 ( GLOBE NEWSWIRE ) -- Ultragenyx Pharmaceutical Inc. ( NASDAQ: RARE ) , a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultrarare genetic diseases, today announced that it will host a conference ...
RARE Reports New Upbeat Data From Sanfilippo Syndrome Drug Study
Ultragenyx announces new safety and efficacy data from its pivotal study of its investigational candidate, UX111, for patients with Sanfilippo syndrome type A.
Ultragenyx Announces New Data Demonstrating that Treatment with UX111 AAV Gene Therapy Significantly Improved Clinical Function Across Multiple Developmental Domains in Children with Sanfilippo Syndrome Type A ( MPS IIIA ) Correlated with Sustained Reductions in CSF-HS
Modified intent-to-treat group demonstrated +22.7 point ( p<0.0001 ) treatment effect in the mean Bayley-III cognitive raw score compared to natural history data ( ages 24-60 months ...
